Prospective open pilot study on the use of ciclosporin for feline allergic skin disease

Noli, Chiara; Scarampella, Fabia

doi:10.1111/j.1748-5827.2006.00110.x

Cited by 35 publications

(60 citation statements)

References 23 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ciclosporin treatment in cats has been associated with toxoplasmosis, 6,7 post‐transplant malignant neoplasia, 8,9 diarrhoea, 3,4 vomiting, hyperactivity, increased appetite, 4 anorexia 10 and gingival hyperplasia 11 . This is similar to dogs, in which gingival hyperplasia 12 and gastrointestinal (GI) upsets 13 have also been described.…”

Section: Introductionmentioning

confidence: 91%

See 1 more Smart Citation

Adverse events in 50 cats with allergic dermatitis receiving ciclosporin

Heinrich¹,

McKeever²,

Eisenschenk³

2011

Veterinary Dermatology

View full text Add to dashboard Cite

Ciclosporin is an immunosuppressive drug that has been used to treat allergies and other immune-mediated diseases in cats, dogs and humans. Information about the adverse effects of ciclosporin in cats has been limited to smaller studies and case reports. Adverse effects in dogs are mainly gastrointestinal in nature, but humans can also experience hypertension and altered renal function. The aim of this retrospective case series study was to document the occurrence and clinical appearance of adverse events in cats receiving ciclosporin to treat allergic skin disease. The medical records of 50 cats with allergic dermatitis treated with oral ciclosporin (1.9-7.3 mg/kg/day) were reviewed. Adverse events occurred in 66% (33 cats). Adverse events likely to be associated with ciclosporin included the following: vomiting or diarrhoea within 1-8 weeks of receiving ciclosporin (24%), weight loss (16%), anorexia and subsequent hepatic lipidosis (2%) and gingival hyperplasia (2%). Other adverse events less likely to be associated with ciclosporin therapy included the following: weight gain (14%), dental tartar and gingivitis (10%), otitis (4%), chronic diarrhoea (4%), inflammatory bowel disease with indolent gastrointestinal lymphoma (2%), urinary tract infection (2%), cataract (2%), elevated liver enzymes (2%), hyperthyroidism and renal failure (2%) and transient inappropriate urination (2%). Some cats experienced multiple adverse events. Case-control studies are needed to prove cause and effect of ciclosporin with regard to these adverse events.

show abstract

Section: Introductionmentioning

confidence: 91%

“…The use of ciclosporin is gaining acceptance for treatment of feline allergic dermatitis, as several studies and anecdotal reports have demonstrated efficacy and apparent safety 3,4 . The true safety of this drug is of concern, as only limited data are available that specifically address the adverse effects of ciclosporin in cats 5–7 …”

Section: Introductionmentioning

confidence: 99%

Adverse events in 50 cats with allergic dermatitis receiving ciclosporin

Heinrich¹,

McKeever²,

Eisenschenk³

2011

Veterinary Dermatology

View full text Add to dashboard Cite

show abstract

“…Recently, CsA has been reported as an effective drug for the long-term management of pruritus in human and canine atopic dermatitis (AD) [10,11,22,30]. In addition, several clinical trials have revealed that CsA is also effective for controlling pruritus in feline skin diseases [21,34].…”

mentioning

confidence: 99%

Cyclosporine A Inhibits Transcription of Cytokine Genes and Decreases The Frequencies of IL-2 Producing Cells in Feline Mononuclear Cells

2008

View full text Add to dashboard Cite

ABSTRACT. Cyclosporine A (CsA) has been widely used for suppression of transplant rejection and controlling pruritus in allergic dermatitis in humans, dogs and cats. CsA is known to suppress the expression of inflammatory cytokines, including IL-2, IL-4, IFN-γ and TNF-α in humans, dogs and experimental mice. However, little is known about the immunomodulating effect of CsA in cats. The aim of this study was to evaluate the effects of CsA on the expression of inflammatory cytokines in feline peripheral blood mononuclear cells (PBMC). Real-time PCR analyses with Concanavalin A (ConA)-stimulated PBMC obtained from 5 cats revealed that the expression of mRNAs for IL-2, IL-4, IFN-γ and TNF-α was inhibited by CsA in a dose-dependent manner. Moreover, an enzyme-linked immunospot (ELISPOT) assay, which is capable of detecting IL-2 secreting cells as single spots, revealed that the frequency of IL-2 secreting cells in ConA-stimulated feline PBMC was significantly reduced in the presence of CsA. These results might provide an explanation for the mechanisms of action of CsA in the suppression of transplant rejection and the control of pruritus in cats.

show abstract

“…Recently this cyclic oligopeptide, which is able to block the transcription of cytokine genes in activated T cells, is being increasingly used in veterinary medicine [4]. In veterinary medicine, cyclosporine has been reported to be effective for the treatment of a number of dermatologic diseases and ophthalmologic problems [4,10,11]. Recent reports [1,4] suggested that the cyclosporine is the effective therapeutic options for GME in dogs.…”

mentioning

confidence: 99%

A Comparison of Combination Therapy (Cyclosporine plus Prednisolone) with Sole Prednisolone Therapy in 7 Dogs with Necrotizing Meningoencephalitis

Jung

Kang

Park

et al. 2007

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

ABSTRACT. Administration of immunosuppressive doses of glucocorticosteroids is the traditional primary treatment in necrotizing meningoencephalitis (NME) in dogs. However, response is variable and clinical signs often recur quickly with tapering dosage. Prognosis is poor and long-term therapy causes many complications. In the present study, we compared the long-term effects of combination (cyclosporine plus prednisolone) therapy with sole prednisolone therapy in management in dogs with NME. All NME cases in this study were examined with magnetic resonance imaging and cerebrospinal fluid analysis, and confirmed by histopathologic examination. The mean survival time of combination therapy group was 305.7 ± 94.7 days. The mean survival time of sole prednisolone therapy group was 58.3 ± 30.5 days. This case report demonstrates that combination treatment of cyclosporine with prednisolone is more effective in survival time than administration of only prednisolone in NME cases.

show abstract

Prospective open pilot study on the use of ciclosporin for feline allergic skin disease

Abstract: Ciclosporin may be helpful in symptomatically treating signs of feline allergic skin disease. However, it is important to remember that ciclosporin is not licensed for use in cats.

Cited by 35 publications

References 23 publications

Adverse events in 50 cats with allergic dermatitis receiving ciclosporin

Adverse events in 50 cats with allergic dermatitis receiving ciclosporin

Cyclosporine A Inhibits Transcription of Cytokine Genes and Decreases The Frequencies of IL-2 Producing Cells in Feline Mononuclear Cells

A Comparison of Combination Therapy (Cyclosporine plus Prednisolone) with Sole Prednisolone Therapy in 7 Dogs with Necrotizing Meningoencephalitis

Contact Info

Product

Resources

About